Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalent Inc (NY: CTLT )

55.76 -0.04 (-0.07%)
Streaming Delayed Price Updated: 2:55 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 816,007
Open 55.91
Bid (Size) 55.74 (3)
Ask (Size) 55.78 (2)
Prev. Close 55.80
Today's Range 55.70 - 56.05
52wk Range 31.80 - 60.20
Shares Outstanding 170,341,553
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)
From Robbins LLP
Via Business Wire
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts foresee Novo and Eli Lilly maintaining dominance in the obesity market, fueled... 
Via Benzinga

Performance

YTD
+23.77%
+23.77%
1 Month
-0.34%
-0.34%
3 Month
+14.45%
+14.45%
6 Month
+29.25%
+29.25%
1 Year
+29.46%
+29.46%

More News

Read More
Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
From Robbins LLP
Via GlobeNewswire
Beyond The Numbers: 6 Analysts Discuss Catalent Stock
Via Benzinga
(CTLT) - Analyzing Catalent's Short Interest
Via Benzinga
In-Depth Examination Of 5 Analyst Recommendations For Catalent
Via Benzinga
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
Via The Motley Fool
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Via Talk Markets
Did Novo Nordisk Just Get a Jump on Eli Lilly?
Via The Motley Fool
Exposures Product Safety
The Top 3 Pharma Stocks to Buy in March2024
Via InvestorPlace
Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug
Via Benzinga
Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
From Catalent, Inc.
Via Business Wire
Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk
Via Benzinga
Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why
Via The Motley Fool
Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
Via Benzinga
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
Via Benzinga
CATALENT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalent, Inc. - CTLT
From Kahn Swick & Foti, LLC
Via Business Wire
S&P 500's surge to new highs: Bull trap hiding in plain sight?
Via MarketBeat
Topics ETFs Economy Stocks
Exposures Interest Rates US Equities
Nearly Half Of S&P 500 Stocks Trade Below 50-Day Moving Average: Which One Is The Cheapest?
Via Benzinga
Topics Stocks
Exposures US Equities
Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs
Via Benzinga
Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?
Via The Motley Fool
Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited
Via The Motley Fool
Catalent, Inc. Reports Second Quarter Fiscal 2024 Results
From Catalent, Inc.
Via Business Wire
US Stocks Set To Open Higher, Finish Week Stronger Amid Mixed Earnings: Analyst Sees Another Leg-Up Ahead Of Historically Weak March
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.